Home >> Protein Tyrosine Kinase >> c-Met >> c-Met Inhibitors >> 
United States (Change Country)

SU11274

Catalog No. S1080 5 5 2 Customer Review(s) Product Citations8 Product Citation(s)
Price Availability Quantity
$ 70 Yes
$ 120 Yes
$ 470 Yes
$ 2170 Yes
 
Bulk Inquiry?
processing...
You can order by phone, email or fax

Tel: +1-832-582-8158    Fax: +1-713-796-9816
Email: [email protected]
Free Overnight Delivery on all orders over $ 500.

Order SU11274 now
and get it on

SU11274 Chemical Structure

Bio Information

SU11274 is a highly specific inhibitor of c-Met , with in vitro IC50 for the Met enzyme at 0.012 μmol/L. The inhibitor did not affect other tyrosine kinase oncoproteins, including BCR-ABL, TEL-JAK2, TEL-PDGF_R, or TEL-ABL. Inhibition of the Met kinase activity by SU11274 led to time- and dose-dependent reduced cell growth. [1]
Further study shows SU11274 belongs to a class of small molecule RTK inhibitors that exert their activity by competing for the Mg-ATP complex binding pocket, which results in inhibition of kinase activity and subsequent downstream signaling. [2]

References:

[1] Oncogene 2004;23:5387–5393

[2] Cancer Res 2005;65:1479-1488

Chemical Information

Molecular Weight (WM): 568.09
Formula:

C28H30CIN5O4S
Solubility(R.T.:25°C): DMSO 92mg/mL 
Water <1mg/mL 
Ethanol 2mg/mL 

Quality Control

View current batch:

Research Area

Protein Tyrosine Kinase >> c-Met >> c-Met Inhibitors

Recommended Screening Libraries

Related Inhibitors

Information  
PF-2341066 (Crizotinib) is a potent inhibitor of c-Met and ALK with IC50 of 11 nM and 24 nnM, respectivley.
  • 5mg
  • $ 110
  • 10mg
  • $ 170
PHA-665752 is a potent, selective and ATP-competitive c-Met inhibitor with IC50 of 9 nM.
  • 5mg
  • $ 70
  • 10mg
  • $ 120
PF-04217903 is a selective ATP-competitive c-Met inhibitor with IC50 of 4.8 nM.
  • 5mg
  • $ 110
  • 10mg
  • $ 160
XL880 (GSK1363089, EXEL-2880) is an ATP-competitive inhibitor of MET and KDR with IC50 of 0.4 nM and 0.9 nM, respectively.
  • 5mg
  • $ 170
  • 50mg
  • $ 870
SGX-523 is a selective Met inhibitor with IC50 of 4 nM.
  • 5mg
  • $ 170
  • 10mg
  • $ 270

Related Antibodies

Information  
Reactivity: 薛亚红

SU11274 has been referenced in 8 publications.

Autocrine activation of the MET receptor tyrosine kinase in acute myeloid leukemia.
Mutant p53 enhances MET trafficking and signalling to drive cell scattering and invasion.
Acquired MET expression confers resistance to EGFR inhibition in a mouse model of glioblastoma multiforme.
Rhodocetin-αβ-induced Neuropilin-1-cMet Association Triggers Restructuring of Matrix Contacts in Endothelial Cells.
Identification of basophils as a major source of hepatocyte growth factor in chronic myeloid leukemia: a novel mechanism of BCR-ABL1-independent disease progression.
Macroporous hydrogel micropillars for quantifying Met kinase activity in cancer cell lysates.
Regulation of microRNA expression by hepatocyte growth factor in human head and neck squamous cell carcinoma.
In vitro evaluation of the Aurora kinase inhibitor VX-680 for Hepatoblastoma.

We have 2 customer reviews of SU11274.

  • (1)
  • (1)
  • (0)
  • (0)
  • (0)
  • (0)
  • (0)
  • (0)
  • (0)

Average Customer Review

(2 customer reviews)

  • Click to enlarge

  • ;Cancer Sci, 2011, 102(12), 2164-71.
    SU11274 purchased from Selleck


  • Click to enlarge

  • Data independently produced by ;Dr. Zhang of Tianjin Medical University
    SU11274 purchased from Selleck

Our scientific support team are available to answer any questions or queries.
Fill out an inquiry form for SU11274 for help.

Quality Matters

This product has been referenced in

+ See All 8 Product Citations of SU11274

Check our customer reviews


Click to enlarge

;Cancer Sci, 2011, 102(12), 2164-71.


Click to enlarge

Data independently produced by ;Dr. Zhang of Tianjin Medical University

Your Recent History

Keywords:buy SU11274 | SU11274 supplier | purchase SU11274 | SU11274 cost | SU11274 manufacturer | order SU11274 | SU11274 distributor